Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (211-220 of 275) with videos related to

Pageof 28
Sort By:
Journal of the National Cancer Institute|May 5, 2005
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancerFederico Cappuzzo, Fred R Hirsch, Elisa Rossi, et al.
Journal of Clinical Medicine|October 14, 2022
Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right ParenchymaAnna La Salvia, Raffaella Carletti, Monica Verrico, et al.
Science (New York, N.Y.)|April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingJeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.
The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
The Lancet. Respiratory Medicine|March 30, 2019
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony S K Mok, Makoto Nishio, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|November 12, 2024
Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinomaFilippo Tommaso Gallina, Fabiana Letizia Cecere, Riccardo Tajè, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancerMartin Reck, Luis Paz-Ares, Paolo Bidoli, et al.
Clinical Lung Cancer|September 23, 2014
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitorsLorenza Landi, Marcello Tiseo, Rita Chiari, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 30, 2018
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access programMarina Chiara Garassino, Lucio Crinò, Annamaria Catino, et al.
Pageof 28

Showing results (211-220 of 275) with videos related to

Sort By:
Pageof 28
Journal of the National Cancer Institute|May 5, 2005
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancerFederico Cappuzzo, Fred R Hirsch, Elisa Rossi, et al.
Journal of Clinical Medicine|October 14, 2022
Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right ParenchymaAnna La Salvia, Raffaella Carletti, Monica Verrico, et al.
Science (New York, N.Y.)|April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingJeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.
The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
The Lancet. Respiratory Medicine|March 30, 2019
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony S K Mok, Makoto Nishio, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|November 12, 2024
Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinomaFilippo Tommaso Gallina, Fabiana Letizia Cecere, Riccardo Tajè, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancerMartin Reck, Luis Paz-Ares, Paolo Bidoli, et al.
Clinical Lung Cancer|September 23, 2014
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitorsLorenza Landi, Marcello Tiseo, Rita Chiari, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 30, 2018
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access programMarina Chiara Garassino, Lucio Crinò, Annamaria Catino, et al.
Pageof 28